These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 18075273

  • 1. Positive and negative implications of tumor necrosis factor neutralization for the pathogenesis of multiple sclerosis.
    Taoufik E, Tseveleki V, Euagelidou M, Emmanouil M, Voulgari-Kokota A, Haralambous S, Probert L.
    Neurodegener Dis; 2008; 5(1):32-7. PubMed ID: 18075273
    [Abstract] [Full Text] [Related]

  • 2. Leukemia inhibitory factor is produced by myelin-reactive T cells from multiple sclerosis patients and protects against tumor necrosis factor-alpha-induced oligodendrocyte apoptosis.
    Vanderlocht J, Hellings N, Hendriks JJ, Vandenabeele F, Moreels M, Buntinx M, Hoekstra D, Antel JP, Stinissen P.
    J Neurosci Res; 2006 Apr; 83(5):763-74. PubMed ID: 16477612
    [Abstract] [Full Text] [Related]

  • 3. [Pathogenesis of multiple sclerosis: status of research].
    Hartung HP.
    Wien Med Wochenschr; 1996 Apr; 146(19-20):520-7. PubMed ID: 9082652
    [Abstract] [Full Text] [Related]

  • 4. Immunologic aspects of multiple sclerosis.
    Boppana S, Huang H, Ito K, Dhib-Jalbut S.
    Mt Sinai J Med; 2011 Apr; 78(2):207-20. PubMed ID: 21425265
    [Abstract] [Full Text] [Related]

  • 5. Immunobiology of oligodendrocytes in multiple sclerosis.
    Ruffini F, Chojnacki A, Weiss S, Antel JP.
    Adv Neurol; 2006 Apr; 98():47-63. PubMed ID: 16400826
    [No Abstract] [Full Text] [Related]

  • 6. Therapeutic effects of combined treatment with ribavirin and tiazofurin on experimental autoimmune encephalomyelitis development: clinical and histopathological evaluation.
    Stojkov D, Lavrnja I, Pekovic S, Dacic S, Bjelobaba I, Mostarica-Stojkovic M, Stosic-Grujicic S, Jovanovic S, Nedeljkovic N, Rakic L, Stojiljkovic M.
    J Neurol Sci; 2008 Apr 15; 267(1-2):76-85. PubMed ID: 17996253
    [Abstract] [Full Text] [Related]

  • 7. Proinflammatory cytokines regulate antigen-independent T-cell activation by two separate calcium-signaling pathways in multiple sclerosis patients.
    Martino G, Grohovaz F, Brambilla E, Codazzi F, Consiglio A, Clementi E, Filippi M, Comi G, Grimaldi LM.
    Ann Neurol; 1998 Mar 15; 43(3):340-9. PubMed ID: 9506551
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
    Kieseier BC, Hartung HP.
    Exp Neurol; 2007 Jan 15; 203(1):1-4. PubMed ID: 17069803
    [No Abstract] [Full Text] [Related]

  • 11. DNA-based vaccines: the future of multiple sclerosis therapy?
    Stüve O, Cravens PD, Eagar TN.
    Expert Rev Neurother; 2008 Mar 15; 8(3):351-60. PubMed ID: 18345967
    [Abstract] [Full Text] [Related]

  • 12. Multiple sclerosis: an immune or neurodegenerative disorder?
    Trapp BD, Nave KA.
    Annu Rev Neurosci; 2008 Mar 15; 31():247-69. PubMed ID: 18558855
    [Abstract] [Full Text] [Related]

  • 13. The pathology of MS: new insights and potential clinical applications.
    Pittock SJ, Lucchinetti CF.
    Neurologist; 2007 Mar 15; 13(2):45-56. PubMed ID: 17351524
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Administration of a monomeric CCL2 variant to EAE mice inhibits inflammatory cell recruitment and protects from demyelination and axonal loss.
    Brini E, Ruffini F, Bergami A, Brambilla E, Dati G, Greco B, Cirillo R, Proudfoot AE, Comi G, Furlan R, Zaratin P, Martino G.
    J Neuroimmunol; 2009 Apr 30; 209(1-2):33-9. PubMed ID: 19232440
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The future of multiple sclerosis treatment.
    Cohen JA.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S55-61. PubMed ID: 19200869
    [Abstract] [Full Text] [Related]

  • 19. Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis.
    Zamvil SS, Steinman L.
    Neuron; 2003 Jun 05; 38(5):685-8. PubMed ID: 12797954
    [Abstract] [Full Text] [Related]

  • 20. [Multiple sclerosis: from the immune system to inflammatory demyelination and irreversible neurodegeneration].
    Sindic CJ.
    Bull Mem Acad R Med Belg; 2002 Jun 05; 157(7-9):391-8; discussion 398-400. PubMed ID: 12647378
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.